Skip to main content
Caplight Logo









Imperagen

Imperagen

Private
ManchesterHealthcare & Life Scienceshttps://imperagen.com/

Last Round

Seed

May 21, 2026

Total Funding Raised

$17.69M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Imperagen is a biotechnology company that provides a digital enzyme evolution platform to accelerate enzyme engineering for the pharmaceutical and chemical industries.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Smart Manufacturing

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

enzyme engineeringbiocatalyststechbioprotein designai-driven biologyautomated wet labbiotechnologysynthetic biologyin-silico designbiocatalysiscomputational biologydrug discoveryindustrial biotechlab automationprotein engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Imperagen Comparables

Compare Imperagen with similar companies based on industry and business-model similarity.

Imperagen comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Zymvol Biomodeling
88%
Ligo Biosciences
87%
Biomatter
84%

Imperagen Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 21, 2026
SeedMay 21, 2024
GrantMar 14, 2024
SeedAug 2, 2022

Key People

Founding team and executive leadership

Andrew A.

Founder And CIO

Founding Team

Tim Eyes

Co-Founder Chief Product Officer CPO

Founding Team

Guy Levy-Yurista

Chief Executive Officer

Executive Team

Rob Wilson

Chief Operating Officer

Executive Team

Imperagen Investors

Notable investors and investment history

Imperagen investors
InvestorRounds
IQ CapitalSeed
Innovate UKGrant
Northern GritstoneSeed
PXN VenturesSeed
PXN GroupSeed
PXN VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 21, 2026

    $5M round led by PXN Group

  • Jan 21, 2026

    Grew 20% QoQ from 15 to 18 employees.

Imperagen Filings

Explore SEC and related filing metadata, where available.

Imperagen filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Imperagen's valuation, stock price, and market status.

Is Imperagen a public or private company?

Imperagen is a private company.

What is the current stock price of Imperagen?

Imperagen is a private company with no public stock price. No recent secondary market data is available.

How much is Imperagen worth (valuation)?

Valuation information for Imperagen is not publicly available.

Can I buy Imperagen stock?

Imperagen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Imperagen's last funding round?

Imperagen's most recent funding round was Seed on May 21, 2026.

Who are the main investors in Imperagen?

Key investors in Imperagen include PXN Ventures, PXN Group, PXN Ventures.

Will Imperagen IPO soon?

No public IPO plans have been announced for Imperagen.

How can I track Imperagen secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Imperagen's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersManchester
Employee Range15
Year Founded2021
Last FundingMay 21, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?